This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Exelixis

Stocks in this article: EXEL CTIC VNDA NVS MDVN JNJ TTNP.OB

Cell Therapeutics' CEO Jim Bianco needs retail investors to buy into his story that pixantrone has a shot at FDA approval because the company must raise more money. Cell Therapeutics runs out of cash in the first quarter of next year -- that's before FDA will issue a second approval decision in April.

Bianco raises money by selling discounted company shares to fast-money funds rounded up by Rodman & Renshaw. These funds, which don't give a rat's posterior about Cell Therapeutics or pixantrone, make quick profits by selling their discounted shares at market price to mostly retail investors who naively and wrongly believe the rags-to-riches story that Bianco sells so well.

Cell Therapeutics is very good at raising money but is very, very bad at developing drugs.

Pixantrone is, and always will be, a me-too chemotherapy drug for lymphoma with marginal efficacy and a questionable safety profile. No one is clamoring for pixantrone. FDA rejected the drug in April 2010, one month after an advisory panel voted unanimously to recommend against its approval. Let's repeat that: An entire panel of cancer experts -- people who treat cancer patients for a living -- didn't think pixantrone was good enough for approval. Not a single expert on the panel supported the drug.

Cell Therapeutics will tell you FDA biased the panel against pixantrone by insisting incorrectly that the phase III study upon which the drug was being reviewed was a statistical failure. Part of this appeal process entailed Cell Therapeutics convincing FDA that the pixantrone study was not a statistical failure and deserved another review.

The more relevant question is whether pixantrone provides a clinically meaningful benefit to lymphoma patients. The problem facing Cell Therapeutics in this "do-over" review is that the pixantrone data have not changed for the better even if the study's statistical significance might have improved. Let's not forget that the "PIX301" study only enrolled 140 of a planned 320 patients. Twenty-eight clinical sites in the U.S. managed to enroll just eight patients. None of these U.S. patients responded to pixantrone.

3 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs